MedTrace Logo

ERAS Program Improves Recovery of HCC Patient Undergoing Hepatectomy

NCT03104920 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2017-04-07

No results posted yet for this study

Summary

The worldwide introduction of multimodal enhanced recovery programs has also changed perioperative care in patients who undergo liver resection. This study will be performed to assess a comprehensive care package for patients with hepatocellular carcinoma (HCC) undergoing hepatectomy with the aim of minimal physiological disturbance in the peri-operative period. Peri-operative opioid-sparing analgesia with few gastrointestinal (GI) effects and reduced requirement for intravenous fluid therapy, early ambulation and promoted GI function recovery were centered to this plan.

Conditions

Interventions

PROCEDURE

ERAS Program

An ERAS pathway comprises of optimized management of diet, mobilization, multimodal perioperative analgesia and GI function recovery modalities.

PROCEDURE

Traditional treatment

A traditional perioperative management for HCC.

Sponsors & Collaborators

  • feng xiaobin

    lead OTHER

Principal Investigators

  • Kuansheng Ma, Doctor · Third Military Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-27
Primary Completion
2018-09-30
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03104920 on ClinicalTrials.gov